Kermit Lloyd, MD
Neurology · Newport News, VANPI 1851325328
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $207,493 of the $257,191 with a category attached, or 80.7%. 19 manufacturers reported payments, led by Biogen at 49.2% of the total. Among neurology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 433 payments — averaging $593.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$126K
- EMD Serono, Inc.$98K
- TG Therapeutics, Inc.$31K
- AstraZeneca$550
- Novartis$444
- Sanofi$259
- plus $1K from 13 others
Across 368 payments — averaging $1533.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$168K
- Adamas Pharmaceuticals, Inc.$117K
- Novartis$97K
- Biogen$60K
- Eisai Inc.$44K
- Alkermes, Inc.$29K
- plus $49K from 3 others
What the payments were for
- Consulting fees$23,9619%
- Speaking & faculty fees$207,49381%
- Travel & lodging$14,0515%
- Food & beverage$11,2964%
- Education$3900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 187 | $126,478 |
| EMD Serono, Inc. | 125 | $97,598 |
| TG Therapeutics, Inc. | 34 | $30,811 |
| AstraZeneca | 9 | $550 |
| Novartis | 30 | $444 |
| Sanofi | 11 | $259 |
| Ceribell, Inc. | 1 | $211 |
| Genentech, Inc. | 7 | $193 |
| AbbVie(2 entities) | 9 | $167 |
| Medtronic | 1 | $147 |
| Amgen(2 entities) | 6 | $122 |
| Genentech USA, Inc. | 4 | $63 |
| Livanova USA, Inc. | 2 | $31 |
| Lundbeck LLC | 1 | $31 |
| Johnson & Johnson | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 2 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavenclad$94,574
- Vumerity$48,389
- TYSABRI$39,003
- BRIUMVI$30,458
- TECFIDERA$27,249
- PLEGRIDY$7,744
- AVONEX$988
- ULTOMIRIS$425
- POCKET EEG DEVICE$211
- SYNCHROMEDII$147
How this compares
$257,191 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MavencladCladribine | 12 | $1,042,998 |
| BriumviUblituximab-Xiiy | 20 | $489,780 |
| Kesimpta PenOfatumumab | 35 | $400,746 |
| OcrevusOcrelizumab | 12 | $400,591 |
| VumerityDiroximel Fumarate | 40 | $320,088 |
| TecfideraDimethyl Fumarate | 25 | $224,965 |
| GilenyaFingolimod Hcl | 16 | $167,252 |
| RebifInterferon Beta-1a/Albumin | 14 | $147,275 |
| TysabriNatalizumab | 13 | $105,934 |
| Teriflunomide | 30 | $103,729 |
| CopaxoneGlatiramer Acetate | 13 | $72,174 |
| Aimovig AutoinjectorErenumab-Aooe | 67 | $44,327 |
| UbrelvyUbrogepant | 43 | $43,278 |
| Emgality PenGalcanezumab-Gnlm | 47 | $38,844 |
| Nurtec OdtRimegepant Sulfate | 18 | $32,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Mavenclad, Rebif | $97,598 | $1,190,27326 claims |
| BiogenVumerity, Tecfidera, Tysabri | $126,478 | $650,98778 claims |
| TG Therapeutics, Inc.Briumvi | $30,811 | $489,78020 claims |
| Genentech, Inc.Ocrevus | $193 | $400,59112 claims |
| NovartisGilenya | $444 | $167,25216 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $13 | $72,17413 claims |
| AbbVieUbrelvy, Qulipta | $167 | $71,59468 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 neurology providers in Virginia.
Other neurology in Newport News
- Ramsey FalconerAlexandria$2M
- Robert ShinCharlottesville$1.7M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
- Jill CramerChristiansburg$598K
- Rahul DaveFairfax$540K
- Daniel HardyRichmond$382K
- Ingrid Loma MillerNorfolk$364K
- Carmen FuentesNorfolk$339K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.